August 2018 Newsletter

August 30, 2018:

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

The change applies to physician-administered and other Part B drugs starting Jan. 1, 2019.

August 30, 2018:

Alcon Withdraws CyPass Device over Endothelial Cell Loss

The move followed analysis of five-year data in subjects.

August 30, 2018:

Ivantis Hydrus Gains US FDA Approval

The device is indicated for use in mild to moderate primary open-angle glaucoma in conjunction with cataract surgery.

August 30, 2018:

Roche, Glaukos Bet on Sustained Drug Delivery

Both companies plan to gain approval of new products within four years.

August 30, 2018:

Dompe’s Oxervate is First Treatment Approved in US for Neurotrophic Keratitis

Company officials said the eye drop formulation is the first-ever topical biologic approved in ophthalmology.

August 30, 2018:

Regeneron Gains US Approval for 12-Week Dosing of Eylea

In two Phase III trials, 51 percent of wet AMD patients maintained BCVA gains at the dosing level in the second year.

August 30, 2018:

US FDA Approves Sun Pharma’s Cequa for Dry Eye

The topical treatment is the third prescription drug for the indication in the US.

August 30, 2018:

Imprimis Plans to Earn $100 Million by 2021

CEO Mark Baum said his vision is for the company to be the most important pharmaceutical vendor to US ophthalmologists.

August 30, 2018:

‘Modicare’ Could Boost Cataract Surgeries in India

The government program will provide health insurance to 100 million poor families.

August 30, 2018:

Market Report: Indian Ophthalmic Market to Grow at 7.6 Percent Rate through 2023

Market Scope forecasts robust growth in the country, with new regulations likely to expand access to health care.

August 30, 2018:

Market Report: Ophthalmic Laser Market Expected to Total $400 Million in 2018

Expanding access to care will offset declining use of photocoagulation for retinal disease.

August 30, 2018:

Rheon’s eyeWatch Adjustable Glaucoma Device Implanted in Three UK Patients

The device is manipulated after implantation by a magnetic pen.

August 30, 2018:

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

The companies will share equally in US profits and losses for EDIT-101.

August 30, 2018:

Kala Gains FDA Approval for Inveltys for Treatment of Postsurgical Inflammation, Pain

The company said it expects to launch its twice-daily ocular corticosteroid in early 2019.

August 30, 2018:

Google’s DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

The company said the next step is to validate the software in clinical trials.

August 30, 2018:

STAAR Surgical Leads Fundraising Efforts with $77.9 Million Public Offering

Other companies raised $21 million, bringing the total for the past month to $98.9 million.

August 30, 2018:

Vienna Set for 2018 ESCRS Congress, plus EURETINA, EuCornea meetings

The combined conference is Europe’s largest assembly of ophthalmologists and ophthalmic product vendors.

August 30, 2018:

Market Scope Weekly Polls

August 30, 2018:

August 2018 News Briefs

Social media